Methods
This pilot trial was an open, randomised, parallel group study
investigating the effect of nebulised unfractionated sodium heparin
(Cristalia Ltda; Brazil, 25,000 IU) in patients admitted to two
hospitals in the state of Sao Paulo, Brazil (Sao Roque Hospital and
Santa Casa de Sorocaba Hospital) between February 25th, 2021, and July
14th, 2021. The trial identification UTN code is U111-1263-3136 and all
patients gave their written informed consent to participate in this
study which was approved by the Ethics Committee of the University of
Sao Paulo – Biomedical Sciences Institute.